Current state and novel approaches of antiplatelet therapy
An unresolved problem with clinical use of antiplatelet therapy is that a significant number of individuals either still get thrombosis or run the risk of life-threatening bleeding. Antiplatelet drugs are widely used clinically, either chronically for people at risk of athero/thrombotic disease or t...
| Main Authors: | , , , |
|---|---|
| Format: | Journal Article |
| Published: |
Lippincott Williams and Wilkins
2015
|
| Online Access: | http://hdl.handle.net/20.500.11937/27777 |
| _version_ | 1848752356817108992 |
|---|---|
| author | Metharom, P. Berndt, Michael Baker, R. Andrews, R. |
| author_facet | Metharom, P. Berndt, Michael Baker, R. Andrews, R. |
| author_sort | Metharom, P. |
| building | Curtin Institutional Repository |
| collection | Online Access |
| description | An unresolved problem with clinical use of antiplatelet therapy is that a significant number of individuals either still get thrombosis or run the risk of life-threatening bleeding. Antiplatelet drugs are widely used clinically, either chronically for people at risk of athero/thrombotic disease or to prevent thrombus formation during surgery. However, a subpopulation may be resistant to standard doses, while the platelet targets of these drugs are also critical for the normal hemostatic function of platelets. In this review, we will briefly examine current antiplatelet therapy and existing targets while focusing on new potential approaches for antiplatelet therapy and improved monitoring of effects on platelet reactivity in individuals, ultimately to improve antithrombosis with minimal bleeding. Primary platelet adhesion-signaling receptors, glycoprotein (GP)Ib-IX-V and GPVI, that bind von Willebrand factor/collagen and other prothrombotic factors are not targeted by drugs in clinical use, but they are of particular interest because of their key role in thrombus formation at pathological shear. |
| first_indexed | 2025-11-14T08:07:20Z |
| format | Journal Article |
| id | curtin-20.500.11937-27777 |
| institution | Curtin University Malaysia |
| institution_category | Local University |
| last_indexed | 2025-11-14T08:07:20Z |
| publishDate | 2015 |
| publisher | Lippincott Williams and Wilkins |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | curtin-20.500.11937-277772017-09-13T15:11:56Z Current state and novel approaches of antiplatelet therapy Metharom, P. Berndt, Michael Baker, R. Andrews, R. An unresolved problem with clinical use of antiplatelet therapy is that a significant number of individuals either still get thrombosis or run the risk of life-threatening bleeding. Antiplatelet drugs are widely used clinically, either chronically for people at risk of athero/thrombotic disease or to prevent thrombus formation during surgery. However, a subpopulation may be resistant to standard doses, while the platelet targets of these drugs are also critical for the normal hemostatic function of platelets. In this review, we will briefly examine current antiplatelet therapy and existing targets while focusing on new potential approaches for antiplatelet therapy and improved monitoring of effects on platelet reactivity in individuals, ultimately to improve antithrombosis with minimal bleeding. Primary platelet adhesion-signaling receptors, glycoprotein (GP)Ib-IX-V and GPVI, that bind von Willebrand factor/collagen and other prothrombotic factors are not targeted by drugs in clinical use, but they are of particular interest because of their key role in thrombus formation at pathological shear. 2015 Journal Article http://hdl.handle.net/20.500.11937/27777 10.1161/ATVBAHA.114.303413 Lippincott Williams and Wilkins unknown |
| spellingShingle | Metharom, P. Berndt, Michael Baker, R. Andrews, R. Current state and novel approaches of antiplatelet therapy |
| title | Current state and novel approaches of antiplatelet therapy |
| title_full | Current state and novel approaches of antiplatelet therapy |
| title_fullStr | Current state and novel approaches of antiplatelet therapy |
| title_full_unstemmed | Current state and novel approaches of antiplatelet therapy |
| title_short | Current state and novel approaches of antiplatelet therapy |
| title_sort | current state and novel approaches of antiplatelet therapy |
| url | http://hdl.handle.net/20.500.11937/27777 |